Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.
Litigation Timeline
Ultra Sheen Launches — First Commercial Lye Relaxer for Black Women
George E. Johnson's Johnson Products launches Ultra Sheen, the first commercially marketed sodium hydroxide-based hair relaxer targeting Black women. The product launches an industry that will grow to nearly $1 billion.
MDL Science Day — Court Receives Scientific Overview
Judge Rowland conducts a Science Day, receiving non-adversarial scientific presentations from both sides. Daubert hearings on general causation experts are scheduled for April–June 2026, with bellwether trials expected in 2027.
FTC Orders Warning Labels After Scalp Burn Complaints
The Federal Trade Commission orders Johnson Products to add warning labels to lye-based relaxers following consumer complaints of severe scalp burns and hair damage. This is the first regulatory action targeting hair relaxer safety.
First No-Lye Relaxer (Gentle Treatment) Introduced
Johnson Products introduces Gentle Treatment, the first commercial no-lye relaxer using guanidine carbonate. While marketed as gentler, no-lye relaxers still contain EDCs including parabens, phthalates, and formaldehyde-releasing agents.
Chemical Testing Reveals 84% of EDCs Unlabeled
James-Todd et al. publish testing data finding 45 endocrine-disrupting chemicals in hair products — with 84% NOT disclosed on product labels. Cyclosiloxanes, parabens, and phthalates detected at highest concentrations.
Sister Study Reveals 2.19x Ovarian Cancer Risk
White et al. publish findings from the NIEHS Sister Study in Carcinogenesis showing that frequent hair straightener use is associated with a 2.19x increased risk of ovarian cancer.
Sister Study Reveals 2.55x Uterine Cancer Risk — Lawsuits Flood In
Chang et al. publish the landmark JNCI study showing frequent hair straightener use doubles uterine cancer risk (HR 2.55). The findings generate widespread media coverage and trigger hundreds of lawsuits within weeks.
MDL 3060 Established in Northern District of Illinois
The Judicial Panel on Multidistrict Litigation consolidates all federal hair relaxer cancer lawsuits into MDL 3060 under Judge Mary M. Rowland in the Northern District of Illinois (Chicago).
FDA Proposes Formaldehyde Ban in Hair Straighteners
The FDA proposes its first rule directly targeting hair relaxer ingredients — a ban on formaldehyde and formaldehyde-releasing chemicals. The rule has not been finalized despite multiple missed deadlines.
Black Women's Health Study Confirms Uterine Cancer Link
Bertrand et al. publish findings from the first large-scale study entirely within a Black women cohort (44,798 participants), confirming >50% increased uterine cancer risk among long-term relaxer users.
Notable Verdicts & Settlements
MDL 3060 Bellwether Trial (Pending)
VerdictDaubert hearings on general causation are scheduled for April–June 2026. Bellwether trial selection is narrowed to ~5,230 eligible cancer cases. First trials expected mid-2027. No verdict has been reached yet.
Comparable: Talcum Powder Ovarian Cancer — $6.5B Settlement Trust
VerdictJohnson & Johnson established a $6.5 billion settlement trust to resolve approximately 60,000 talcum powder ovarian cancer claims. The parallel is direct: a consumer product marketed to women (disproportionately women of color), containing undisclosed carcinogens, causing reproductive cancers through chronic exposure.
Comparable: Roundup Cancer — $10.9B Global Settlement
VerdictBayer/Monsanto reached a $10.9 billion settlement for Roundup glyphosate cancer claims — approximately $165,000 per claimant for the ~66,000 resolved cases. Demonstrates precedent for massive global settlements when epidemiological evidence links a consumer product to cancer.
Comparable: Talcum Powder — $2.12B Missouri Verdict (Later Reversed)
Verdict$2.12 billion verdict for 22 women who alleged talcum powder caused ovarian cancer. While later reversed on jurisdictional grounds, the verdict demonstrated jury willingness to award massive damages for cancer-causing consumer products marketed to women without cancer warnings.
Comparable: Uterine Cancer Delayed Diagnosis — Average Verdicts
VerdictMedical malpractice verdicts for uterine cancer delayed diagnosis range from $430,000 to $9.9 million, with an average around $2.5 million. These provide a baseline for uterine cancer case values, though product liability claims may yield higher amounts due to corporate conduct and failure-to-warn theories.
Comparable: Zantac Cancer — Bellwether Trial Outcomes
VerdictThe Zantac cancer MDL resulted in defense verdicts after Daubert challenges excluded plaintiffs' general causation experts. This represents a cautionary benchmark — the April–June 2026 Daubert hearings in the hair relaxer MDL are the most critical near-term event. If plaintiffs' experts are excluded, the litigation could face similar challenges.
Comparable: Camp Lejeune Water Contamination — $21B Framework
VerdictThe Camp Lejeune Justice Act established a $21 billion settlement framework for approximately 500,000 claimants exposed to toxic water. Like hair relaxers, the case involved chronic exposure to endocrine disruptors and carcinogens through a trusted institution, with disproportionate impact on vulnerable populations.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full Hair Relaxer Cancer Lawsuits Case Page